Notification Waiver Determination

TA Associates – MedEnvision

Acquisition	TA Associates Management, L.P (**TA Associates**) applied for a notification waiver in respect of its proposed acquisition, via Anchor Bidco B.V., of the share capital in MedEnvision International BV and its subsidiaries (**MedEnvision**), as described in the transaction documents provided as part of the application (the **Acquisition**). As part of the Acquisition, existing shareholders in MedEnvision will rollover a portion of their existing shareholding to retain minority stakes. This will result in TA Associates indirectly holding a majority shareholding in, and having sole control over, MedEnvision.
Determination	The Australian Competition and Consumer Commission has determined under section 51ABV(1)(a) of the *Competition and Consumer Act 2010* (Cth) that the Acquisition is not required to be notified.
Date of determination	4 November 2026

Parties to the Acquisition	The acquirer, TA Associates, is headquartered in Boston, Massachusetts, USA. It is a private equity firm investing in companies across five target industries: technology, financial services, healthcare, consumer, and business services. TA Associates together with its managed funds is the ultimate controller of Anchor Bidco B.V. The target, MedEnvision, is a Belgian medical device company headquartered in Westerlo, Belgium. MedEnvision carries on the business of development, manufacturing, distribution, marketing and sale of medical products used to improve the efficiency and effectiveness of operations in the field of orthopaedics.
Explanation for determination	In making this notification waiver determination, the Australian Competition and Consumer Commission (the **ACCC**) has considered the information provided with the notification waiver application and had regard to the factors in section 51ABV(2)(b) of the *Competition and Consumer Act 2010* (Cth) (the **Act**). Based on the information provided in the application, the ACCC considers that the Acquisition is unlikely to give rise to any material lessening of competition, given there is no horizontal overlap or vertical relationship between TA Associates (and its connected entities) and MedEnvision in Australia. In these circumstances, the ACCC does not consider it necessary to reach a concluded view on the likelihood of the notification thresholds being met.

	Given that material competition concerns are unlikely to arise, the ACCC has determined that the Acquisition is not required to be notified. The ACCC considers that the determination is consistent with the object of the Act and the interests of consumers in promoting competition. For more information about the ACCC's approach to considering notification waiver applications and to assessing competition effects more generally, see the ACCC's guidance on notification waivers and merger assessment guidelines.

Determination made by Commissioner Woodward pursuant to a delegation under section 25(1) of the Act